Literature DB >> 27983775

Carnitine and γ-Butyrobetaine Stimulate Elimination of Meldonium due to Competition for OCTN2-mediated Transport.

Edgars Liepinsh1, Elina Makarova1, Eduards Sevostjanovs1, Dace Hartmane1, Helena Cirule1, Olga Zharkova-Malkova1, Solveiga Grinberga1, Maija Dambrova1,2.   

Abstract

Meldonium (3-(2,2,2-trimethylhydrazinium)propionate) is the most potent clinically used inhibitor of organic cation transporter 2 (OCTN2). Inhibition of OCTN2 leads to a decrease in carnitine and acylcarnitine contents in tissues and energy metabolism optimization-related cardioprotective effects. The recent inclusion of meldonium in the World Anti-Doping Agency List of Prohibited Substances and Methods has raised questions about the pharmacokinetics of meldonium and its unusually long elimination time. Therefore, in this study, the rate of meldonium washout after the end of the treatment was tested with and without administration of carnitine, γ-butyrobetaine (GBB) and furosemide to evaluate the importance of competition for OCTN2 transport in mice. Here, we show that carnitine and GBB administration during the washout period effectively stimulated the elimination of meldonium. GBB induced a more pronounced effect on meldonium elimination than carnitine due to the higher affinity of GBB for OCTN2. The diuretic effect of furosemide did not significantly affect the elimination of meldonium, carnitine and GBB. In conclusion, the competition of meldonium, carnitine and GBB for OCTN2-mediated transport determines the pharmacokinetic properties of meldonium. Thus, due to their affinity for OCTN2, GBB and carnitine but not furosemide stimulated meldonium elimination. During long-term treatment, OCTN2-mediated transport ensures a high muscle content of meldonium, while tissue clearance depends on relatively slow diffusion, thus resulting in the unusually long complete elimination period of meldonium.
© 2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27983775     DOI: 10.1111/bcpt.12729

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  2 in total

1.  Crystal structures of binary compounds of meldonium 3-(1,1,1-tri-methyl-hydrazin-1-ium-2-yl)prop-ano-ate with sodium bromide and sodium iodide.

Authors:  Alexander Y Nazarenko
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-05-22

Review 2.  Radiation-induced Adaptive Response: New Potential for Cancer Treatment.

Authors:  C Norman Coleman; Iris Eke; Adeola Y Makinde; Sunita Chopra; Sandra Demaria; Silvia C Formenti; Shannon Martello; Michelle Bylicky; James B Mitchell; Molykutty J Aryankalayil
Journal:  Clin Cancer Res       Date:  2020-06-17       Impact factor: 13.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.